You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 63 No. 2, February 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Observation
 This Article
 •Abstract
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (9)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Neurogenetics
 •Genetic Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

A Missense Mutation in the Coiled-Coil Domain of the KIF5A Gene and Late-Onset Hereditary Spastic Paraplegia

Mariangela Lo Giudice, BS; Marcella Neri, MD; Michele Falco, BS; Maurizio Sturnio, BS; Elisa Calzolari, MD; Daniela Di Benedetto, PhD; Marco Fichera, PhD

Arch Neurol. 2006;63:284-287.

ABSTRACT

Background  To our knowledge, up to now, only 2 mutations in the KIF5A gene, a member of the kinesin superfamily, have been identified as the molecular cause of early-onset autosomal dominant hereditary spastic paraparesis (ADHSP).

Objective  To assess the genetic defect in a family with late-onset ADHSP.

Patients and Methods  Only the proband agreed to undergo complete neurological testing and mutational analysis. The proband was screened for mutations in the spastin, atlastin, NIPA1, and KIF5A genes, either by denaturing high-performance liquid chromatography or sequence analysis.

Results  The history of the family was consistent with ADHSP characterized by late onset of the disease. Mutational analysis results were negative for the spastin, atlastin, and NIPA1 genes but identified a missense mutation (c.1082C>T) in the coiled-coil coding region of the KIF5A gene.

Conclusions  This finding enlarges the phenotypic spectrum of ADHSP linked to KIF5A and enhances the role of that gene in the epidemiology of this disease. We propose that the KIF5A gene should be routinely analyzed in patients with hereditary spastic paraplegia negative for spastin and atlastin mutations.



INTRODUCTION
 Jump to Section
 •Top
 •Introduction
 •Methods
 •Results
 •Comment
 •Author information
 •References

Hereditary spastic paraplegia (HSP) is a heterogeneous group of neurodegenerative diseases characterized by progressive weakness, spasticity, and loss of vibratory sense in the lower limbs. Clinically, HSPs are divided into "uncomplicated" (symptoms confined to lower extremity weakness, bladder disturbance, and, to a lesser extent, impaired position sense in the legs) or "complicated" (when additional neurological deficits are present).1

Recent genetic studies revealed that at least 28 loci of HSP have been associated with autosomal dominant (ADHSP), recessive, or X chromosome–linked transmission, but only 9 of the responsible genes have been identified. Among them, spastin (SPG4), atlastin (SPG3A), KIF5A (SPG10), HSP60 (SPG13),2 and, more recently, NIPA1 (SPG6)3 have been associated with pure ADHSP. The functions of several of these genes are related to axonal transport or intracellular trafficking. Herein we report on a new mutation in the KIF5A gene found in the index case of a pedigree with ADHSP.


METHODS
 Jump to Section
 •Top
 •Introduction
 •Methods
 •Results
 •Comment
 •Author information
 •References

PATIENTS

This Italian family (Figure 1) was identified through the neurological examination of the proband (3-9). Nine additional relatives were reported as having difficulties in gait, but only the proband agreed to give DNA for genetic testing.


Figure 500771
View larger version (17K):
[in this window]
[in a new window]
Figure 1. Pedigree of the studied family. Arrow indicates the proband. Filled symbols represent affected individuals and slash marks, deceased individuals.


GENETIC STUDIES

Genomic DNA was extracted from peripheral blood samples by standard protocols after written informed consent. Mutational analysis was performed on the spastin and KIF5A genes by denaturing high-performance liquid chromatography (DHPLC) as previously described4-5 while the atlastin and NIPA1 genes were analyzed by direct sequencing using polymerase chain reaction (PCR) primers and protocols either previously described (atlastin)6 or available on request (NIPA1). The PCR products were purified using the QIAquick PCR purification kit (Qiagen, Hilden, Germany) and bidirectionally sequenced using the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, Calif). Samples were analyzed on an ABI PRISM 310 automated sequencer (Applied Biosystems).

BIOINFORMATIC ANALYSIS

The effect of the A361V mutation on the coiled-coil structure of KIF5A was predicted using the COILS program.7 The normal and A361V mutant sequences were analyzed using the MTIDK matrix,8 with window lengths of 14, 21, and 28. The hypothetical activation by the mutation of a cryptic splice site was tested using SpliceView software.9


RESULTS
 Jump to Section
 •Top
 •Introduction
 •Methods
 •Results
 •Comment
 •Author information
 •References

PHENOTYPIC DESCRIPTION

The proband (3-9) was a 48-year-old man who experienced difficulty in gait and urinary urgency since the age of 35 years. Neurological examination revealed corticospinal tract deficits affecting the lower extremities with an asymmetry in the physiological range. Major findings were spastic gait and marked hyperreflexia, and extensor plantar response muscle tone was increased during gait as well as at passive mobilization, associated with weakness and pes cavus. No sensory loss or decreased vibration sense were recorded. There was no upper limb involvement. Negative findings in the clinical evaluation were absence of extrapyramidal signs, ataxia, retinal involvement, amyotrophy, mental retardation, dementia, deafness, or epilepsy.

Neurophysiological examination revealed slight abnormalities in evoked motor potential of the lower limbs in the presence of a normal central conduction time. The upper extremities' responses were in the normal range. The evoked sensitive potentials in the lower and upper extremities and the examination results of the optic trait were normal. Peripheric conduction velocities and F waves of the lower extremities were in the normal range, excluding a neuromuscular involvement. Normal magnetic resonance imaging results of the brain and spinal cord excluded structural abnormalities. The differential diagnosis with multiple sclerosis was supported by normal results of cytochemical analysis of cerebrospinal fluid and by the absence of oligoclonal bands. All hematochemical analysis results were in the normal range, in particular the inflammatory index and the folate and vitamin B12 levels.

The familial tree (Figure 1) showed recurrence of gait disturbance in this family in 4 generations. The precise age of disease onset was reported only for the father of our proband, who had clinical symptoms at the age of 50 years, while other affected members were reported to have had an adult onset of spastic gait. No clinical data were available for other family members.

GENETIC ANALYSIS

DNA analysis was only performed on the proband (3-9) because of the unavailability of the other pedigree members. No mutations were found in the SPG4, SPG3A, and NIPA1 genes, although we cannot exclude either the presence of cryptic intronic mutations in these genes or that mutations may have been missed by DHPLC screening, despite its very high sensitivity. Further DHPLC analysis of the KIF5A gene revealed a clear heterozygous elution pattern of the exon 11–related PCR product.

Successive sequence analysis (Figure 2) identified a heterozygous single-nucleotide variant at position 1082 (c.1082C>T) predicted to result in alanine-to-valine substitution at codon 361 (A361V) in the coiled-coil tail region of KIF5A. The affected amino acid is conserved in the KIF5A family of several vertebrate species (Figure 3); moreover, this mutation was not found in a group of 750 unrelated chromosomes from healthy individuals of the same ethnic origin tested by DHPLC, indicating that this was unlikely to be a rare polymorphism and most probably represented the mutation underlying the phenotype observed in the patient studied.


Figure 500772
View larger version (32K):
[in this window]
[in a new window]
Figure 2. Electropherogram of the sequence flanking the c.1082C>T mutation.



Figure 500773
View larger version (55K):
[in this window]
[in a new window]
Figure 3. Comparative analysis of the amino acid sequence (339-376) of the KIF5A protein. Arrow shows the alanine residue affected by the A361V mutation.


BIOINFORMATIC ANALYSIS

The mutation did not show any significant effect either on the coiled-coil structure or on the activation of cryptic splice sites (data not shown).


COMMENT
 Jump to Section
 •Top
 •Introduction
 •Methods
 •Results
 •Comment
 •Author information
 •References

Neurons are an example of extremely polarized cells with axons that reach up to 1 m in length; because axons have little or no protein synthesis machinery, axonal proteins must be synthesized in the cell body. Neurons require an appropriate system of intracellular traffic and an intracellular transport system, and this requirement could be the "Achilles heel" of these large, complex cells.

The KIF5A protein belongs to the superfamily of kinesins, which are molecular motor proteins responsible for many of the major microtubule-dependent transport pathways in neuronal and nonneuronal cells.10 They typically consist of 2 identical, approximately 110- to 120-kD heavy chains and 2 identical, approximately 60- to 70-kD light chains. The heavy chains have a 3-domain structure. The globular N-terminal motor domain, which contains the adenosine triphosphate and microtubule-binding sites, is about 340 amino acids long. The heavy chains of kinesin dimerize through an {alpha}-helical coiled-coil region, the so-called stalk domain. The third domain consists of a C-terminal globular tail that is thought to be involved in light-chain and cargo binding.

To our knowledge, to date, only 2 disease-causing mutations in the KIF5A gene have been described in the literature,5, 11 localized in exons 10 (R280C) and 8 (N256S), respectively. These 2 lesions belong to the region of the kinesin devoted to microtubule binding, known to affect the adenosine triphosphatase activity of the motor domain.12-13

In this study, we identified a novel missense mutation in the KIF5A gene in the proband of a large pedigree with ADHSP. The absence of this mutation was tested in 375 normal controls. Nevertheless, because we were unable to analyze the other members of the family, we cannot exclude that it is a very rare polymorphism that segregates independently from the disease.

This defect occurs in a region adjacent to the globular motor domain (termed the neck region) that permits dimerization and contains a sequence that is predicted to form an {alpha}-helical coiled-coil domain.14 Furthermore, this domain appears to be structurally important for coordinating the activities of the 2 kinesin heads during processive movement along microtubules.14-15

The heptad repeat motif (a, b, c, d, e, f, and g) forms the structural basis of the {alpha}-helical coiled coil and is found in a wide variety of proteins.16 The "a" and "d" positions are usually represented by small nonpolar residues that stabilize the coil. Therefore, substitution of amino acids at these positions may destabilize the protein. In addition, the coiled coil may be further stabilized by salt bridges formed between charged side chains in the "g" and "e" positions of opposing helices. The mechanism by which the A361V mutation results in a pathogenic alteration of KIF5A is not clear because this mutation occurs in the "b" position of the heptad repeat in a residue that is exposed at the surface of the coiled-coil domain, and the replacement of the alanine by the valine does not change the hydrophobic character of the structure.

Interestingly, at least the propositus and his father in this family are characterized by a late onset of disease, whereas the patients previously described5, 11 showed a prevalent juvenile onset of the symptoms, probably reflecting a different pathologic mechanism of this mutation.

Recent reports suggest that about 50% of mutations involved in ADHSP are related to the spastin (40%) and atlastin (10%) genes.17 Among 10 families showing a pure ADHSP who were recently screened for the spastin, atlastin, and KIF5A genes in our laboratory, we found 3,5 1 (unpublished result), and 2 mutations,5 respectively. Although these figures are too small to be significant, we propose that, in the absence of linkage information, the KIF5A gene should be routinely tested in ADHSP.


AUTHOR INFORMATION
 Jump to Section
 •Top
 •Introduction
 •Methods
 •Results
 •Comment
 •Author information
 •References

Correspondence: Marco Fichera, PhD, Laboratorio di Diagnosi Genetica, IRCCS Oasi Maria SS, via Conte Ruggero 73, 94018 Troina (EN), Italy (mfichera{at}oasi.en.it).

Accepted for Publication: August 12, 2005.

Author Contributions: Study concept and design: Lo Giudice. Acquisition of data: Falco and Di Benedetto. Analysis and interpretation of data: Neri, Sturnio, Calzolari, and Fichera. Drafting of the manuscript: Lo Giudice, Neri, Falco, Calzolari, Di Benedetto, and Fichera. Critical revision of the manuscript for important intellectual content: Sturnio. Obtained funding: Lo Giudice and Neri. Administrative, technical, and material support: Falco, Sturnio, and Di Benedetto. Study supervision: Calzolari and Fichera.

Funding/Support: This study was supported by the Italian Ministry of Health, Rome.

Author Affiliations: Genetic Diagnostic Laboratory, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Oasi Maria SS, Troina, Italy (Mss Lo Giudice and Falco, Mr Sturnio, and Drs Di Benedetto and Fichera); Department of Experimental Medicine and Diagnostics, Medical Genetics Service, University of Ferrara, Ferrara, Italy (Drs Neri and Calzolari).


REFERENCES
 Jump to Section
 •Top
 •Introduction
 •Methods
 •Results
 •Comment
 •Author information
 •References

1. McDermott C, White K, Bushby K, et al. Hereditary spastic paraparesis: a review of new developments. J Neurol Neurosurg Psychiatry. 2000;69:150-160. FREE FULL TEXT
2. Reid E. Science in motion: common molecular pathological themes emerge in the hereditary spastic paraplegias. J Med Genet. 2003;40:81-86. FREE FULL TEXT
3. Rainier S, Chai JH, Tokarz D, et al. NIPA1 gene mutations cause autosomal dominant hereditary spastic paraplegia (SPG6). Am J Hum Genet. 2003;73:967-971. FULL TEXT | ISI | PUBMED
4. Falco M, Scuderi C, Musumeci S, et al. Two novel mutations in the spastin gene (SPG4) found by DHPLC mutation analysis. Neuromuscul Disord. 2004;14:750-753. FULL TEXT | ISI | PUBMED
5. Fichera M, Lo Giudice M, Falco M, et al. Evidence of kinesin heavy chain (KIF5A) involvement in pure hereditary spastic paraplegia. Neurology. 2004;63:1108-1110. FREE FULL TEXT
6. Dürr A, Camuzat A, Colin E, et al. Atlastin 1 mutations are frequent in young-onset autosomal dominant spastic paraplegia. Arch Neurol. 2004;61:1867-1872. FREE FULL TEXT
7. Lupas A, Van Dyke M, Stock J. Predicting coiled coils from protein sequences. Science. 1991;252:1162-1164. FREE FULL TEXT
8. Coils documentation. Available at: ftp://ftp.ebi.ac.uk/pub/software/unix/coils-2.2.
9. Webgene SpliceView. The National Research Council Institute for Biomedical Technologies Web site. Available at: http://l25.itba.mi.cnr.it/~webgene/wwwspliceview.html.
10. Hirokawa N. Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science. 1998;279:519-526. FREE FULL TEXT
11. Reid E, Kloos M, Ashley-Koch A, et al. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am J Hum Genet. 2002;71:1189-1194. FULL TEXT | ISI | PUBMED
12. Kikkawa M, Sablin EP, Okada Y, et al. Switch-based mechanism of kinesin motors. Nature. 2001;411:439-445. FULL TEXT | PUBMED
13. Hoenger A, Thormahlen M, Diaz-Avalos R, et al. A new look at the microtubule binding patterns of dimeric kinesins. J Mol Biol. 2000;297:1087-1103. FULL TEXT | ISI | PUBMED
14. Tripet B, Vale RD, Hodges S. Demonstration of coiled-coil interactions within the kinesin neck region using synthetic peptides. J Biol Chem. 1997;272:8946-8956. FREE FULL TEXT
15. Kozielski F, Sack S, Marx A, et al. The crystal structure of dimeric kinesin and implications for microtubule-dependent motility. Cell. 1997;91:985-994. FULL TEXT | ISI | PUBMED
16. Adamson JG, Zhou NE, Hodges RS. Structure, function and application of the coiled-coil protein folding motif. Curr Opin Biotechnol. 1993;4:428-437. FULL TEXT | PUBMED
17. Park SY, Ki CS, Kim HJ, et al. Mutation analysis of SPG4 and SPG3A genes and its implication in molecular diagnosis of Korean patients with hereditary spastic paraplegia. Arch Neurol. 2005;62:1118-1121. FREE FULL TEXT


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intracellular Flow in Optic Nerve Axons: A Mechanism for Cell Death in Glaucoma
Band et al.
IOVS 2009;50:3750-3758.
ABSTRACT | FULL TEXT  

Effect of spastic paraplegia mutations in KIF5A kinesin on transport activity
Ebbing et al.
Hum Mol Genet 2008;17:1245-1252.
ABSTRACT | FULL TEXT  

SPG10 is a rare cause of spastic paraplegia in European families
Schule et al.
J. Neurol. Neurosurg. Psychiatry 2008;79:584-587.
ABSTRACT | FULL TEXT  

1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C
Morfini et al.
Proc. Natl. Acad. Sci. USA 2007;104:2442-2447.
ABSTRACT | FULL TEXT  

When intracellular logistics fails - genetic defects in membrane trafficking
Olkkonen and Ikonen
J. Cell Sci. 2006;119:5031-5045.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.